| Literature DB >> 17351844 |
Stephen Marcella1, Cristine D Delnevo, Steven S Coughlin.
Abstract
BACKGROUND: Today's medical students are being educated at a time when there are no evidence-based guidelines for prostate cancer screening.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17351844 PMCID: PMC1824714 DOI: 10.1007/s11606-006-0015-1
Source DB: PubMed Journal: J Gen Intern Med ISSN: 0884-8734 Impact factor: 5.128
Beliefs Towards Prostate Cancer Screening Among U.S. Medical Students (N = 1,609)
| Agree strongly % | Agree somewhat % | No opinion % | Disagree somewhat % | Disagree strongly % | |
|---|---|---|---|---|---|
| An early screening diagnosis can improve survival for men with prostate cancer | 61.1 | 26.5 | 4.1 | 7.4 | 0.8 |
| The digital rectal examination is an accurate screening test for prostate cancer | 11.3 | 51.5 | 13.5 | 19.8 | 3.9 |
| The PSA test is an accurate screening test for prostate cancer | 11.5 | 43.3 | 18.3 | 21.8 | 5.2 |
| More likely to screen if a patient has a family history of prostate cancer | 53.1 | 30.3 | 7.1 | 5.9 | 3.7 |
| More likely to screen for prostate cancer if a patient is black | 18.4 | 16.9 | 46.7 | 10.7 | 7.4 |
| More likely to screen for prostate cancer if a patient is Hispanic | 3.6 | 11.6 | 61.1 | 14.9 | 8.8 |
N = 1,609: unweighted N.
PSA prostate-specific antigen.
Percentage of U.S. Medical Students Correctly Responding to Statements About Prostate Cancer Screening by Class Year (N = 1,609)
| Class year | Total | ||||
|---|---|---|---|---|---|
| First | Second | Third | Fourth | ||
| The mortality rate for prostate cancer has not declined in recent years (F) | 50.3 | 49.7 | 48.2 | 46.2 | 48.6 |
| Prostatectomy results in improved survival over the natural course of the disease (F)* | 20 | 33.4 | 41.9 | 47.1 | 35.5 |
| ACS recommends routine prostate cancer screening for all men over age 50 (T) | 91.2 | 90.2 | 89.5 | 91.4 | 90.6 |
| A normal PSA level rules out prostate cancer. (F) | 86.3 | 93.5 | 92.1 | 92.6 | 91.1 |
| Randomized control trials have clearly supported PSA prostate cancer screening. (F) | 25.3 | 45.7 | 59.9 | 69.2 | 49.9 |
| Elevated PSA levels almost always indicate a diagnosis of prostate cancer (F) | 58.4 | 78.5 | 90.6 | 90.3 | 79.4 |
| USPSTF recommends routine prostate cancer screening for all men over age 50 (F) | 4.6 | 5.3 | 14.6 | 17.7 | 10.5 |
| The PSA test is highly specific in prostate cancer screening (F) | 58.9 | 78.1 | 81 | 80.8 | 74.6 |
N = 1,609: unweighted N.
ACS American Cancer Society, PSA prostate-specific antigen, USPSTF United States Preventive Services Task Force, F the statement is factually false, T the statement is factually true.
*At the time of the study, evidence in support of prostatectomy did not exist.
Characteristics of U.S. Medical Student Participants (N = 1,609)
| Percent ( | |
|---|---|
| Sex | |
| Male | 56.9 (805) |
| Female | 43.1 (804) |
| Race/ethnicity | |
| White | 64.5 (1,100) |
| Asian | 16.6 (248) |
| Black | 7.7 (118) |
| Hispanic | 6.6 (51) |
| Other | 4.4 (88) |
| Class year | |
| First | 25.4 (369) |
| Second | 24.6 (390) |
| Third | 25.4 (346) |
| Fourth | 24.6 (504) |
| Career orientation | |
| Specialist | 44.5 (670) |
| Generalist | 39.8 (717) |
| Do not know | 15.7 (219) |
| Family history of cancer | |
| Prostate | 10.3 (172) |
| Any other cancer | 61.1 (1,034) |
*Unweighted n.
Characteristics Associated With Prostate Cancer Screening Beliefs Among U.S. Medical Students
| Early screening improves survival | DRE is an accurate screening test | PSA is an accurate screening test | More likely to screen if patient has family history | More likely to screen if patient is black | More likely to screen if patient is Hispanic | |
|---|---|---|---|---|---|---|
| AOR (95%CI) | AOR (95%CI) | AOR (95%CI) | AOR (95%CI) | AOR (95%CI) | AOR (95%CI) | |
| Sex | ||||||
| Male | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
| Female | 1.37 (0.81–2.31) | 0.96 (0.64–1.45) | 0.85 (0.70–1.04) | 1.04 (0.78–1.39) | 1.15 (0.80–1.66) | 1.15 (0.81 –1.64) |
| Medical school year | ||||||
| First | 1.33 (0.68–2.63) | 0.80 (0.57–1.13) | 0.54 (0.36–0.81) | 0.98 (0.66–1.45) | 0.21 (0.13–0.36) | 0.63 (0.32–1.26) |
| Second | 1.05 (0.65–1.70) | 1.82 (1.24–2.69) | 1.70 (1.09–2.64) | 1.98 (1.14–3.43) | 0.60 (0.38–0.95) | 1.06 (0.52–2.15) |
| Third | 1.36 (0.87–2.13) | 1.66 (1.25–2.20) | 1.40 (0.93–2.13) | 1.52 (0.99–2.34) | 1.01 (0.67–1.53) | 1.28 (0.85–1.92) |
| Fourth | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
| Future practice intention | ||||||
| Primary care | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
| Specialty | 1.93 (1.27–2.95) | 1.18 (0.88–1.59) | 1.45 (1.11–1.90) | 0.85 (0.62–1.15) | 0.84 (0.68–1.05) | 0.88 (0.56–1.40) |
| Do not know | 1.20 (0.68–2.09) | 0.90 (0.62–1.32) | 1.14 (0.69–1.88) | 0.65 (0.35–1.23) | 0.86 (0.59–1.26) | 1.13 (0.60–2.13) |
| Race/ethnicity | ||||||
| White | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
| Asian | 0.58 (0.38–0.88) | 0.98 (0.72–1.34) | 0.83 (0.66–1.05) | 1.39 (0.89–2.17) | 0.69 (0.50–0.97) | 1.16 (0.70–1.93) |
| Black | 0.82 (0.33–2.03) | 0.95 (0.57–1.58) | 1.60 (0.98–2.60) | 0.89 (0.50–1.58) | 7.80 (5.32–11.43) | 3.19 (2.17–4.69) |
| Hispanic | 1.20 (0.45–3.20) | 0.78 (0.46–1.33) | 1.08 (0.69–1.70) | 0.75 (0.19–2.95) | 1.58 (0.64–3.86) | 2.30 (1.10–4.83) |
| Other | 0.79 (0.38–1.67) | 1.87 (0.97–3.61) | 0.81 (0.48–1.37) | 0.88 (0.47–1.62) | 1.52 (0.81–2.85) | 2.09 (0.88–4.93) |
| Family history of prostate cancer | ||||||
| No | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
| Yes | 1.03 (0.53–2.02) | 0.94 (0.65–1.35) | 1.73 (1.18–2.54) | 1.60 (0.75–3.40) | 1.24 (0.88–1.75) | 1.46 (0.98–2.16) |
| Knowledge* | ||||||
| Low | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
| Middle | 0.62 (0.35–1.10) | 0.94 (0.57–1.55) | 0.72 (0.51–1.03) | 0.60 (0.33–1.06) | 0.79 (0.62–1.00) | 0.74 (0.49–1.12) |
| High | 0.21 (0.14–0.34) | 0.57 (0.37–0.89) | 0.34 (0.22–0.52) | 0.55 (0.35–0.87) | 0.72 (0.45–1.15) | 0.70 (0.46–1.07) |
DRE digital rectal exam, PSA prostate-specific antigen, AOR adjusted odds ratio, CI confidence interval.
*Assignment by number of statements correctly addressed in Table 2: low 0–3, middle 4–5, and high 6–8.